嗜黏蛋白阿克曼菌在肠道相关疾病中作用的研究进展

doi:10.3969/j.issn.1674-8115.2022.10.016

上海交通大学学报（医学版） ›› 2022, Vol. 42 ›› Issue (10): 1490-1497.doi: 10.3969/j.issn.1674-8115.2022.10.016

• 综述 • 上一篇

嗜黏蛋白阿克曼菌在肠道相关疾病中作用的研究进展

蒋怡¹(), 江平², 张明明¹, 房静远¹()

^1.上海交通大学医学院附属仁济医院消化科，上海市消化疾病研究所，上海 200001
^2.南京大学医学院附属鼓楼医院消化内科，南京 210093

收稿日期:2022-05-07 接受日期:2022-08-28 出版日期:2022-10-17 发布日期:2022-10-17
通讯作者: 房静远 E-mail:jiangyi1501@163.com;jingyuanfang@sjtu.edu.cn
作者简介:蒋怡（1996—），女，硕士生；电子信箱：jiangyi1501@163.com。
基金资助:
国家自然科学基金(81970487)

Research progress in the role of Akkermansia muciniphila in gut-related diseases

JIANG Yi¹(), JIANG Ping², ZHANG Mingming¹, FANG Jingyuan¹()

^1.Shanghai Institute of Digestive Disease, Department of Gastroenterology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200001, China
^2.Department of Gastroenterology, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing 210093, China

Received:2022-05-07 Accepted:2022-08-28 Online:2022-10-17 Published:2022-10-17
Contact: FANG Jingyuan E-mail:jiangyi1501@163.com;jingyuanfang@sjtu.edu.cn
Supported by:
National Natural Science Foundation of China(81970487)

摘要/Abstract

摘要：

嗜黏蛋白阿克曼菌（Akkermansia muciniphila，A. muciniphila）是人类肠道中的常见共生菌之一，可利用黏蛋白作为唯一的碳、氮来源，在肠道内定植和生长。肠道稳态对于维持人体正常生理功能至关重要，肠道功能发生紊乱与代谢疾病、免疫疾病、感染性疾病和肿瘤等的发生、发展密切相关。肠道微生物群是影响肠道健康的关键因素，作为肠道微生物的一员，A. muciniphila在肠道炎症、肠道肿瘤、受肠道紊乱影响的疾病（如肝病、代谢性疾病等）中的作用已被证实，且作用机制亦逐渐被阐明，被认为是一种很有前景的候选益生菌。该文针对A. muciniphila的特征、在肠道中的分布、与肠道相关疾病的关联及作用机制进行综述。

关键词: 嗜黏蛋白阿克曼菌, 炎症, 肿瘤, 益生菌, 肠道菌群

Abstract:

Akkermansia muciniphila (A. muciniphila) is one of the normal gut symbionts using mucin as the sole source of carbon and nitrogen elements to maintain colonization and growth. Intestinal homeostasis is crucial for maintaining physiological functions. Intestinal dysfunction is closely related to the occurrence and development of metabolic diseases, immune diseases, infectious diseases and tumors. Gut microbiota is a key factor that influences the intestinal health. As a member of the gut microbes, A. muciniphila plays a convincing role in intestinal inflammation, intestinal tumor and other intestinal disorders involving diseases such as liver diseases and metabolic diseases. The mechanism is under exploration and revealed gradually. Hence, A. muciniphila is considered to be a promising candidate of probiotics. The characteristics of A. muciniphila, its distribution in the gut, its relationship with gut-related diseases and the mechanism are reviewed.

Key words: Akkermansia muciniphila (A. muciniphila), inflammation, tumor, probiotics, gut microbiota

中图分类号:

R574.4

蒋怡, 江平, 张明明, 房静远. 嗜黏蛋白阿克曼菌在肠道相关疾病中作用的研究进展[J]. 上海交通大学学报（医学版）, 2022, 42(10): 1490-1497.

JIANG Yi, JIANG Ping, ZHANG Mingming, FANG Jingyuan. Research progress in the role of Akkermansia muciniphila in gut-related diseases[J]. Journal of Shanghai Jiao Tong University (Medical Science), 2022, 42(10): 1490-1497.

图/表 3

参考文献 52

1	LYNCH S V, PEDERSEN O. The human intestinal microbiome in health and disease[J]. N Engl J Med, 2016, 375(24): 2369-2379.
2	JAKOBSSON H E, ABRAHAMSSON T R, JENMALM M C, et al. Decreased gut microbiota diversity, delayed Bacteroidetes colonisation and reduced Th1 responses in infants delivered by caesarean section[J]. Gut, 2014, 63(4): 559-566.
3	DERRIEN M, COLLADO M C, BEN-AMOR K, et al. The Mucin degrader Akkermansia muciniphila is an abundant resident of the human intestinal tract[J]. Appl Environ Microbiol, 2008, 74(5): 1646-1648.
4	DERRIEN M, VAUGHAN E E, PLUGGE C M, et al. Akkermansia muciniphila gen. nov., sp. nov., a human intestinal mucin-degrading bacterium[J]. Int J Syst Evol Microbiol, 2004, 54(Pt 5): 1469-1476.
5	HOLD G L, PRYDE S E, RUSSELL V J, et al. Assessment of microbial diversity in human colonic samples by 16S rDNA sequence analysis[J]. FEMS Microbiol Ecol, 2002, 39(1): 33-39.
6	SALZMAN N H, DE JONG H, PATERSON Y, et al. Analysis of 16S libraries of mouse gastrointestinal microflora reveals a large new group of mouse intestinal bacteria[J]. Microbiology (Reading), 2002, 148(Pt 11): 3651-3660.
7	DERRIEN M, VAN PASSEL M W, VAN DE BOVENKAMP J H, et al. Mucin-bacterial interactions in the human oral cavity and digestive tract[J]. Gut Microbes, 2010, 1(4): 254-268.
8	COLLADO M C, DERRIEN M, ISOLAURI E, et al. Intestinal integrity and Akkermansia muciniphila, a mucin-degrading member of the intestinal microbiota present in infants, adults, and the elderly[J]. Appl Environ Microbiol, 2007, 73(23): 7767-7770.
9	COLLADO M C, ISOLAURI E, LAITINEN K, et al. Distinct composition of gut microbiota during pregnancy in overweight and normal-weight women[J]. Am J Clin Nutr, 2008, 88(4): 894-899.
10	SONOYAMA K, FUJIWARA R, TAKEMURA N, et al. Response of gut microbiota to fasting and hibernation in Syrian hamsters[J]. Appl Environ Microbiol, 2009, 75(20): 6451-6456.
11	BELZER C, DE VOS W M. Microbes inside: from diversity to function: the case of Akkermansia[J]. ISME J, 2012, 6(8): 1449-1458.
12	VAN PASSEL M W J, KANT R, ZOETENDAL E G, et al. The genome of Akkermansia muciniphila, a dedicated intestinal mucin degrader, and its use in exploring intestinal metagenomes[J]. PLoS One, 2011, 6(3): e16876.
13	BAJER L, KVERKA M, KOSTOVCIK M, et al. Distinct gut microbiota profiles in patients with primary sclerosing cholangitis and ulcerative colitis[J]. World J Gastroenterol, 2017, 23(25): 4548-4558.
14	EARLEY H, LENNON G, BALFE Á, et al. The abundance of Akkermansia muciniphila and its relationship with sulphated colonic mucins in health and ulcerative colitis[J]. Sci Rep, 2019, 9(1): 15683.
15	KUMP P, WURM P, GRÖCHENIG H P, et al. The taxonomic composition of the donor intestinal microbiota is a major factor influencing the efficacy of faecal microbiota transplantation in therapy refractory ulcerative colitis[J]. Aliment Pharmacol Ther, 2018, 47(1): 67-77.
16	PNG C W, LINDÉN S K, GILSHENAN K S, et al. Mucolytic bacteria with increased prevalence in IBD mucosa augment in vitro utilization of mucin by other bacteria[J]. Am J Gastroenterol, 2010, 105(11): 2420-2428.
17	BIAN X Y, WU W R, YANG L Y, et al. Administration of Akkermansia muciniphila ameliorates dextran sulfate sodium-induced ulcerative colitis in mice[J]. Front Microbiol, 2019, 10: 2259.
18	KANG C S, BAN M, CHOI E J, et al. Extracellular vesicles derived from gut microbiota, especially Akkermansia muciniphila, protect the progression of dextran sulfate sodium-induced colitis[J]. PLoS One, 2013, 8(10): e76520.
19	WANG L J, TANG L, FENG Y M, et al. A purified membrane protein from Akkermansia muciniphila or the pasteurised bacterium blunts colitis associated tumourigenesis by modulation of CD8⁺ T cells in mice[J]. Gut, 2020, 69(11): 1988-1997.
20	HÅKANSSON Å, TORMO-BADIA N, BARIDI A, et al. Immunological alteration and changes of gut microbiota after dextran sulfate sodium (DSS) administration in mice[J]. Clin Exp Med, 2015, 15(1): 107-120.
21	CASTRO-MEJÍA J, JAKESEVIC M, KRYCH Ł, et al. Treatment with a monoclonal anti-IL-12p40 antibody induces substantial gut microbiota changes in an experimental colitis model[J]. Gastroenterol Res Pract, 2016, 2016: 4953120.
22	GANESH B P, KLOPFLEISCH R, LOH G, et al. Commensal Akkermansia muciniphila exacerbates gut inflammation in Salmonella Typhimurium-infected gnotobiotic mice[J]. PLoS One, 2013, 8(9): e74963.
23	SEREGIN S S, GOLOVCHENKO N, SCHAF B, et al. NLRP6 protects Il10 ^-/- mice from colitis by limiting colonization of Akkermansia muciniphila[J]. Cell Rep, 2017, 19(4): 733-745.
24	BAE M, CASSILLY C D, LIU X, et al. Akkermansia muciniphila phospholipid induces homeostatic immune responses[J]. Nature, 2022, 608(7921): 168-173.
25	FAN L N, XU C C, GE Q W, et al. A. muciniphila suppresses colorectal tumorigenesis by inducing TLR2/NLRP3-mediated M1-like TAMs[J]. Cancer Immunol Res, 2021, 9(10): 1111-1124.
26	COLLINS D, HOGAN A M, WINTER D C. Microbial and viral pathogens in colorectal cancer[J]. Lancet Oncol, 2011, 12(5): 504-512.
27	ROUTY B, LE CHATELIER E, DEROSA L, et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors[J]. Science, 2018, 359(6371): 91-97.
28	HOU X Y, ZHANG P, DU H Z, et al. Akkermansia muciniphila potentiates the antitumor efficacy of FOLFOX in colon cancer[J]. Front Pharmacol, 2021, 12: 725583.
29	MILOSEVIC I, VUJOVIC A, BARAC A, et al. Gut-liver axis, gut microbiota, and its modulation in the management of liver diseases: a review of the literature[J]. Int J Mol Sci, 2019, 20(2): 395.
30	GRANDER C, ADOLPH T E, WIESER V, et al. Recovery of ethanol-induced Akkermansia muciniphila depletion ameliorates alcoholic liver disease[J]. Gut, 2018, 67(5): 891-901.
31	WU W R, LV L X, SHI D, et al. Protective effect of Akkermansia muciniphila against immune-mediated liver injury in a mouse model[J]. Front Microbiol, 2017, 8: 1804.
32	FAN Y, PEDERSEN O. Gut microbiota in human metabolic health and disease[J]. Nat Rev Microbiol, 2021, 19(1): 55-71.
33	EVERARD A, BELZER C, GEURTS L, et al. Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity[J]. Proc Natl Acad Sci USA, 2013, 110(22): 9066-9071.
34	SANTACRUZ A, COLLADO M C, GARCÍA-VALDÉS L, et al. Gut microbiota composition is associated with body weight, weight gain and biochemical parameters in pregnant women[J]. Br J Nutr, 2010, 104(1): 83-92.
35	KARLSSON C L J, ONNERFÄLT J, XU J, et al. The microbiota of the gut in preschool children with normal and excessive body weight[J]. Obesity (Silver Spring), 2012, 20(11): 2257-2261.
36	ZHANG X Y, SHEN D Q, FANG Z W, et al. Human gut microbiota changes reveal the progression of glucose intolerance[J]. PLoS One, 2013, 8(8): e71108.
37	CHELAKKOT C, CHOI Y, KIM D K, et al. Akkermansia muciniphila-derived extracellular vesicles influence gut permeability through the regulation of tight junctions[J]. Exp Mol Med, 2018, 50(2): e450.
38	DAO M C, EVERARD A, ARON-WISNEWSKY J, et al. Akkermansia muciniphila and improved metabolic health during a dietary intervention in obesity: relationship with gut microbiome richness and ecology[J]. Gut, 2016, 65(3): 426-436.
39	PLOVIER H, EVERARD A, DRUART C, et al. A purified membrane protein from Akkermansia muciniphila or the pasteurized bacterium improves metabolism in obese and diabetic mice[J]. Nat Med, 2017, 23(1): 107-113.
40	LEE H, KO G. Effect of metformin on metabolic improvement and gut microbiota[J]. Appl Environ Microbiol, 2014, 80(19): 5935-5943.
41	SHIN N R, LEE J C, LEE H Y, et al. An increase in the Akkermansia spp. population induced by metformin treatment improves glucose homeostasis in diet-induced obese mice[J]. Gut, 2014, 63(5): 727-735.
42	LI J, LIN S Q, VANHOUTTE P M, et al. Akkermansia muciniphila protects against atherosclerosis by preventing metabolic endotoxemia-induced inflammation in Apoe ^-/- mice[J]. Circulation, 2016, 133(24): 2434-2446.
43	ZHU L D, LU X X, LIU L, et al. Akkermansia muciniphila protects intestinal mucosa from damage caused by S. pullorum by initiating proliferation of intestinal epithelium[J]. Vet Res, 2020, 51(1): 34.
44	REUNANEN J, KAINULAINEN V, HUUSKONEN L, et al. Akkermansia muciniphila adheres to enterocytes and strengthens the integrity of the epithelial cell layer[J]. Appl Environ Microbiol, 2015, 81(11): 3655-3662.
45	ALAM A, LEONI G, QUIROS M, et al. The microenvironment of injured murine gut elicits a local pro-restitutive microbiota[J]. Nat Microbiol, 2016, 1: 15021.
46	GREGORIEFF A, PINTO D, BEGTHEL H, et al. Expression pattern of Wnt signaling components in the adult intestine[J]. Gastroenterology, 2005, 129(2): 626-638.
47	DERRIEN M, VAN BAARLEN P, HOOIVELD G, et al. Modulation of mucosal immune response, tolerance, and proliferation in mice colonized by the mucin-degrader Akkermansia muciniphila[J]. Front Microbiol, 2011, 2: 166.
48	ANSALDO E, SLAYDEN L C, CHING K L, et al. Akkermansia muciniphila induces intestinal adaptive immune responses during homeostasis[J]. Science, 2019, 364(6446): 1179-1184.
49	MASLOWSKI K M, VIEIRA A T, NG A, et al. Regulation of inflammatory responses by gut microbiota and chemoattractant receptor GPR43[J]. Nature, 2009, 461(7268): 1282-1286.
50	KIM M, FRIESEN L, PARK J, et al. Microbial metabolites, short-chain fatty acids, restrain tissue bacterial load, chronic inflammation, and associated cancer in the colon of mice[J]. Eur J Immunol, 2018, 48(7): 1235-1247.
51	MENG X, ZHANG J R, WU H, et al. Akkermansia muciniphila aspartic protease Amuc_1434* inhibits human colorectal cancer LS174T cell viability via TRAIL-mediated apoptosis pathway[J]. Int J Mol Sci, 2020, 21(9): 3385.
52	CARIO E, GERKEN G, PODOLSKY D K. Toll-like receptor 2 controls mucosal inflammation by regulating epithelial barrier function[J]. Gastroenterology, 2007, 132(4): 1359-1374.

Disease	Mouse model	Determinant	Effect （+/-）
Colitis	DSS induced colitis	Bacteria	-/+^{［17， 20］}
		AmEV	-^［18］
		Amuc_1100	-^［19］
Colitis	Salmonella typhimurium-infected colitis	Bacteria	+^［22］
Colitis	Il10^-/- mice spontaneous colitis	Bacteria	+^［23］
CAC	AOM/DSS induced CAC	Amuc_1100	-^［19］
CRC	Apc^Min/+ mice spontaneous CRC	Bacteria	-^［25］
CRC	HCT116/CT26 subcutaneously transplantation tumor	Bacteria	-^［25］
ALD	Alcohol induced ALD	Bacteria	-^［30］
Liver injury	ConA induced liver injury	Bacteria	-^［31］
Obesity/T2DM	High-fat diet induced obesity/T2DM	Bacteria	-^［33］
Obesity/T2DM	High-fat diet induced obesity/T2DM	Amuc_1100	-^［39］

Disease	Mouse model	Determinant	Effect （+/-）
Colitis	DSS induced colitis	Bacteria	-/+^{［17， 20］}
		AmEV	-^［18］
		Amuc_1100	-^［19］
Colitis	Salmonella typhimurium-infected colitis	Bacteria	+^［22］
Colitis	Il10^-/- mice spontaneous colitis	Bacteria	+^［23］
CAC	AOM/DSS induced CAC	Amuc_1100	-^［19］
CRC	Apc^Min/+ mice spontaneous CRC	Bacteria	-^［25］
CRC	HCT116/CT26 subcutaneously transplantation tumor	Bacteria	-^［25］
ALD	Alcohol induced ALD	Bacteria	-^［30］
Liver injury	ConA induced liver injury	Bacteria	-^［31］
Obesity/T2DM	High-fat diet induced obesity/T2DM	Bacteria	-^［33］
Obesity/T2DM	High-fat diet induced obesity/T2DM	Amuc_1100	-^［39］

[1]	杨文倩, 陈迟琪, 赵路, 曹力元, 夏一秋, 卢智刚, 郑俊克. 免疫抑制性受体LILRB2促进新型冠状病毒刺突蛋白介导的炎症过程[J]. 上海交通大学学报（医学版）, 2022, 42(9): 1188-1196.
[2]	崔锡炜, 钟民衎, 热汗姑丽·艾买尔, 王智超, 李青峰. 人多效蛋白抑制恶性周围神经鞘瘤转移的机制研究[J]. 上海交通大学学报（医学版）, 2022, 42(9): 1225-1238.
[3]	王婕, 吴慧, 卢凌鹏, 杨科峰, 祝捷, 周恒益, 姚蝶, 高雅, 冯宇婷, 刘玉红, 贾洁. 妊娠期糖尿病女性肠道菌群的变化特征及其与血糖、血脂和膳食的相关性[J]. 上海交通大学学报（医学版）, 2022, 42(9): 1336-1346.
[4]	褚云开, 廖春华, 邓华云, 黄雷. 黏蛋白1与肿瘤相关蛋白的调控网络研究[J]. 上海交通大学学报（医学版）, 2022, 42(8): 1024-1033.
[5]	邱佳辉, 蔡谦谦, 杨彦, 程非池, 裘正军, 黄陈. 神经脉管浸润联合肿瘤间质比对结直肠癌预后的预测价值[J]. 上海交通大学学报（医学版）, 2022, 42(8): 1070-1080.
[6]	林家俞, 秦洁洁, 蒋玲曦. 肿瘤微环境中免疫细胞的代谢研究进展[J]. 上海交通大学学报（医学版）, 2022, 42(8): 1122-1130.
[7]	阿婷曦, 邵春益, 傅瑶. 调节性T细胞在眼表疾病中作用的研究进展[J]. 上海交通大学学报（医学版）, 2022, 42(8): 1145-1150.
[8]	邢正文, 吴滢, 王雪莉, 王庆煜, 王文婷, 李治, 张彬, 金晶. 儿童CIC重排肉瘤的临床病理特征[J]. 上海交通大学学报（医学版）, 2022, 42(8): 1151-1157.
[9]	刘宏强, 陆艳青, 高宇轩, 王一云, 王传东, 张晓玲. 构建高效载体OPEI沉默TRAF6促进骨关节炎软骨再生的研究[J]. 上海交通大学学报（医学版）, 2022, 42(7): 846-857.
[10]	王雨心, 孙瑞琪, 刘坚华, 何伟娜. 开发用于肿瘤微环境成像的pH敏感荧光探针[J]. 上海交通大学学报（医学版）, 2022, 42(7): 875-884.
[11]	张琳程, 钟华. 结节病的发病机制与临床治疗研究进展[J]. 上海交通大学学报（医学版）, 2022, 42(7): 931-938.
[12]	卢雨, 王昊, 巴乾. 肠道菌群在肝癌发生发展及治疗中的作用研究进展[J]. 上海交通大学学报（医学版）, 2022, 42(7): 939-944.
[13]	雷海桃, 田雪梅, 金芳全. 细胞因子信号转导抑制因子与类风湿关节炎的相关性研究进展[J]. 上海交通大学学报（医学版）, 2022, 42(7): 945-951.
[14]	戴芹, 王伟铭. IgA肾病细胞模型中的炎症表达及丙戊酸钠的抗炎作用[J]. 上海交通大学学报（医学版）, 2022, 42(6): 751-757.
[15]	胡晓, 张鑫, 谷阳. 体质量与C1q肿瘤坏死因子相关蛋白1在心肌梗死患者中的交互作用[J]. 上海交通大学学报（医学版）, 2022, 42(6): 786-791.

嗜黏蛋白阿克曼菌在肠道相关疾病中作用的研究进展

Research progress in the role of Akkermansia muciniphila in gut-related diseases

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

图/表 3

参考文献 52

相关文章 15

编辑推荐

Metrics